Literature DB >> 11834944

Effect of target cell availability on HIV-1 production in vitro.

Elissa J Schwartz1, Avidan U Neumann, Avelino V Teixeira, Leslie A Bruggeman, Jay Rappaport, Alan S Perelson, Paul E Klotman.   

Abstract

OBJECTIVE: The recovery of CD4 target cells following antiretroviral therapy may facilitate virus production and escape from antiretroviral suppression. To address this hypothesis, we directly examined whether the CD4 target cell number increases viral production in the presence of suboptimal therapy.
DESIGN: The effect of the CD4 T cell number on HIV-1 replication with a suboptimal dose of zidovudine was studied in vitro.
METHODS: Varying numbers of CD4 T cells were infected with HIV-1 and treated with 1 nM zidovudine. Virus production was measured by p24 antigen capture enzyme-linked immunosorbent assay. Partial sequencing of HIV-1 pol was performed to assess zidovudine-resistant mutations.
RESULTS: Wild type virus production was found to increase eightfold in cultures with 100 x 10(4) cells compared with cultures with 10 x 10(4) cells. The IC90 of zidovudine was 4 logs higher in cultures with 16 x 10(4) cells compared with cultures with 1 x 10(4) cells. No zidovudine-resistant mutations were found.
CONCLUSION: Target cell availability may play a direct role in wild type HIV-1 resurgence following therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834944     DOI: 10.1097/00002030-200202150-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

1.  CD4+ target cell availability determines the dynamics of immune escape and reversion in vivo.

Authors:  Janka Petravic; Liyen Loh; Stephen J Kent; Miles P Davenport
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

2.  Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection.

Authors:  Zhi-Qiang Zhang; Stephen W Wietgrefe; Qingsheng Li; Marta Dykhuizen Shore; Lijie Duan; Cavan Reilly; Jeffrey D Lifson; Ashley T Haase
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-02       Impact factor: 11.205

3.  Modelling Mutation in Equine Infectious Anemia Virus Infection Suggests a Path to Viral Clearance with Repeated Vaccination.

Authors:  Elissa J Schwartz; Christian Costris-Vas; Stacey R Smith
Journal:  Viruses       Date:  2021-12-06       Impact factor: 5.048

4.  Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.

Authors:  Elissa J Schwartz; Robert J Smith
Journal:  Vaccines (Basel)       Date:  2014-05-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.